

The 2nd International Electronic Conference on Medicine

MDPI

11-13 November 2025 | Online

The Effects of Therapeutic Cannabis and Cannabinoids in Parkinson's Disease: An Overview of Meta-Analyses

Michele Antonelli (1), Elena Mazzoleni (2), Davide Donelli (3)

(1) Private Practice (Reggio Emilia, Italy); (2) University of Modena and Reggio Emilia (Modena, Italy); (3) University Hospital of Parma (Parma, Italy)

INTRODUCTION & AIM

Cannabis and cannabinoids have been investigated for their potential therapeutic effects in Parkinson's disease, but clinical findings remain scant and inconsistent.

This study provides a systematic overview of meta-analyses assessing the impact of therapeutic cannabis and its derivatives on health outcomes in patients with Parkinson's disease.



Cannabis Sativa
Franz Eugen Köhler's
Medizinal-Pflanzen (1887)
Public Domain Picture

METHOD

A <u>comprehensive search of PubMed, EMBASE, Web of Science, and Google Scholar</u> (up to April 2025) identified meta-analyses evaluating cannabis-based interventions in Parkinson's disease.

Eligible studies reported pooled estimates of effects on neurological symptoms. The most significant findings from the included studies were summarized and qualitatively analyzed.

RESULTS & DISCUSSION

After screening a total of 975 research items, seven meta-analyses of clinical and laboratory studies, primarily randomized controlled trials (RCTs), were identified [1-7].

One analysis of five RCTs demonstrated that *pure CBD* or synthetic THC significantly improved disease symptoms (SMD=-0.41, p=0.004) [1]. In contrast, a meta-analysis of three RCTs evaluating various cannabis extracts found *no* significant effect on the Unified Parkinson Disease Rating Scale (UPDRS) total score (SMD=-0.18, p=0.48) [2]. However, another analysis combining two RCTs and two non-RCTs reported a significant improvement in the UPDRS total score (MD=-4.19, p=0.03) [3]. Other meta-analyses yielded mixed results [4-6].

With regard to *pain management* in Parkinson's disease, a study confirmed that cannabinoids are an effective treatment option [4].

Additionally, a meta-analysis of preclinical *studies in animal models* indicated *notable enhancements in motor function*, with improved rotarod performance (MD=31.63 s, p=0.003) and reduced pole test times (MD=-1.51 s, p=0.028) [7].

CONCLUSION

While meta-analyses of clinical studies suggest some benefits of specific cannabinoid formulations, findings are uncertain. Preclinical data, however, demonstrate interesting motor improvements.

Further well-designed RCTs are warranted to clarify the therapeutic role of cannabis in Parkinson's disease management.

REFERENCES

- 1. Bilbao, A.; Spanagel, R. Medical Cannabinoids: A Pharmacology-Based Systematic Review and Meta-Analysis for All Relevant Medical Indications. BMC Med 2022, 20, 259, doi:10.1186/s12916-022-02459-1.
- 2. DeVera, L.R.; Pacaña, A.M.Q. Cannabis Sativa as a Possible Treatment for Alleviating Both Motor and Nonmotor Symptoms of Parkinson's Disease: A Meta-Analysis, De La Salle University, 2023.
- 3. Guillermo, J.G.C., Jr; Gochioco, D.C.T.; Merin, J.I.G.; Matibag, V.I.P.; Zialcita, M.K.M. Use of Cannabis in the Improvement in the Unified Parkinson's Disease Rating Scale Score of Parkinson's Disease: A Meta Analysis. Philippine Journal of Neurology 2018, 21, 10–15.
- 4. Qureshi, A.R.; Rana, A.Q.; Malik, S.H.; Rizvi, S.F.H.; Akhter, S.; Vannabouathong, C.; Sarfraz, Z.; Rana, R. Comprehensive Examination of Therapies for Pain in Parkinson's Disease: A Systematic Review and Meta-Analysis. Neuroepidemiology 2018, 51, 190–206, doi:10.1159/000492221.
- 5. Thanabalasingam, S.J.; Ranjith, B.; Jackson, R.; Wijeratne, D.T. Cannabis and Its Derivatives for the Use of Motor Symptoms in Parkinson's Disease: A Systematic Review and Meta-Analysis. Ther Adv Neurol Disord 2021, 14, 17562864211018561, doi:10.1177/17562864211018561.
- 6. Urbi, B.; Corbett, J.; Hughes, I.; Owusu, M.A.; Thorning, S.; Broadley, S.A.; Sabet, A.; Heshmat, S. Effects of Cannabis in Parkinson's Disease: A Systematic Review and Meta-Analysis. J Parkinsons Dis 2022, 12, 495–508, doi:10.3233/JPD-212923.
- 7. Urbi, B.; Lee, Y.; Hughes, I.; Thorning, S.; Broadley, S.A.; Sabet, A.; Heshmat, S. **Effects of Cannabinoids in Parkinson's Disease Animal Models: A Systematic Review and Meta-Analysis**. BMJ Open Sci 2022, 6, e100302, doi:10.1136/bmjos-2022-100302.